Patents by Inventor Martin Clive Hutchings
Martin Clive Hutchings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8604051Abstract: Novel processes for the preparation of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety and intermediates thereto are provided. The compounds prepared by the present processes may be useful, for example, as selective inhibitors of human MEK (MAPKK) enzymes, and are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. The present processes may offer improved yields, chemical or stereochemical purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.Type: GrantFiled: February 6, 2013Date of Patent: December 10, 2013Assignee: UCB Pharma S.A.Inventors: Martin Clive Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
-
Patent number: 8487101Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.Type: GrantFiled: July 20, 2010Date of Patent: July 16, 2013Assignee: UCB Pharma S.A.Inventors: Daniel Christopher Brookings, Martin Clive Hutchings, Barry John Langham
-
Patent number: 8394822Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.Type: GrantFiled: September 5, 2012Date of Patent: March 12, 2013Assignee: UCB Pharma, S.A.Inventors: Martin Clive Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
-
Patent number: 8350037Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.Type: GrantFiled: January 22, 2010Date of Patent: January 8, 2013Assignee: UCB Pharma, S.A.Inventors: James Andrew Johnson, Daniel Christopher Brookings, Martin Clive Hutchings, Barry John Langham, Judi Charlotte Neuss
-
Patent number: 8283359Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.Type: GrantFiled: July 30, 2008Date of Patent: October 9, 2012Assignee: UCB Pharma S.A.Inventors: Martin Clive Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
-
Publication number: 20110021558Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.Type: ApplicationFiled: July 20, 2010Publication date: January 27, 2011Applicant: UCB Pharma S.A.Inventors: Daniel Christopher Brookings, Martin Clive Hutchings, Barry John Langham
-
Patent number: 7795256Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 3-position by an arylcarbonyl or heteroaryl-carbonyl moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.Type: GrantFiled: October 22, 2004Date of Patent: September 14, 2010Assignee: UCB Pharma S.A.Inventors: Rikki Peter Alexander, Jeremy Martin Davis, Martin Clive Hutchings, Victoria Elizabeth Laing, Graham Peter Trevitt
-
Publication number: 20100179124Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.Type: ApplicationFiled: January 22, 2010Publication date: July 15, 2010Applicant: UCB Pharma S.A.Inventors: James Andrew Johnson, Daniel Christopher Brookings, Martin Clive Hutchings, Barry John Langham, Judi Charlotte Neuss
-
Publication number: 20100179185Abstract: The present invention concerns novel 3-aminothienopyridinone derivatives of the formula I, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.Type: ApplicationFiled: November 23, 2007Publication date: July 15, 2010Applicant: UCB PHARMA, S.A.Inventors: Jeremy Martin Davis, Daniel Christopher Brookings, Barry John Langham, Martin Clive Hutchings
-
Publication number: 20090264411Abstract: A series of 4,5,6,7-tetrahydrothieno[2,3-c]azepin-8-one derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.Type: ApplicationFiled: February 13, 2009Publication date: October 22, 2009Applicant: UCB Pharma S.A.Inventors: Victoria Elizabeth Laing, Daniel Christopher Brookings, Rachel Jane Carbery, Jose Miguel Gascon Simorte, Martin Clive Hutchings, Barry John Langham, Martin Alexander Lowe
-
Publication number: 20040180914Abstract: Pyrimidines of formula (1) are described 1Type: ApplicationFiled: March 29, 2004Publication date: September 16, 2004Applicant: Celltech R&D LimtiedInventors: Mark James Batchelor, David Festus Charles Moffat, Jeremy Martin Davis, Martin Clive Hutchings
-
Patent number: 6579983Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R1 is a hydrogen atom or a straight or branched chain alkyl group; R2 is a —X1—R3 group where X1 is a direct bond or a linker atom or group, and R3 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.Type: GrantFiled: June 16, 2000Date of Patent: June 17, 2003Assignee: Celltech R&D LimitedInventors: Mark James Batchelor, David Festus Charles Moffat, Jeremy Martin Davis, Martin Clive Hutchings
-
Patent number: 6552029Abstract: Compounds of general formula (1) are described wherein: Ar is an optionally substituted aromatic group; R2 is a hydrogen or halogen atom or a group —X1—R2a where X1 is a direct bond or a linker atom or group, and R2a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R3 is an optionally substituted heterocycloalkyl group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective protein tyrosine kinase inhibitors, particularly the kinases ZAP-70 and syk and are of use in the prophylaxis and treatment of immune or allergic diseases and diseases involving inappropriate platelet activation.Type: GrantFiled: October 20, 1999Date of Patent: April 22, 2003Assignee: Celltech R&D LimitedInventors: Peter David Davis, David Festus Charles Moffat, Mark James Batchelor, Martin Clive Hutchings, David Mark Parry
-
Publication number: 20020147339Abstract: Pyrimidines of formula (1) are described 1Type: ApplicationFiled: May 20, 2002Publication date: October 10, 2002Inventors: Mark James Batchelor, David Festus Charles Moffat, Jeremy Martin Davis, Martin Clive Hutchings
-
Publication number: 20020115692Abstract: Tryptophan derivatives of formula (1) are described: 1Type: ApplicationFiled: November 20, 2001Publication date: August 22, 2002Inventors: Sarah Catherine Archibald, David Festus Charles Moffat, Martin Clive Hutchings, Anne Marie Foley
-
Patent number: 6337335Abstract: Compounds of formula (1) are described: and the salts, solvates, hydrates and N-oxides thereof, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings given in claim 1. The compounds are selective inhibitors of protein kinases, especially src-family protein kinases and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role.Type: GrantFiled: October 20, 1999Date of Patent: January 8, 2002Assignee: Celltech Therapeutics LimitedInventors: Martin Clive Hutchings, Peter David Davis, David Festus Charles Moffat
-
Patent number: 6235746Abstract: Compounds of general formula (1) are described: wherein R1 is a hydrogen or halogen atom or an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group or a group selected from hydroxyl (—OH), substituted hydroxyl, thiol (—SH), substituted thiol, amino (—NH2), or substituted amino; R2 and R3, which may be the same or different, is each an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R4 is a hydrogen atom or a straight or branched chain alkyl group; R5 is a hydrogen atom or an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R6 is a hydrogen or halogen atom or an amino (—NH2), substituted amino, nitro, carboxyl (—CO2H) or esterified carboxyl group or a group —X1—R6a where X1 is a direct bond or a linker atom or group and R6a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; X is a direct bond or a linker atom orType: GrantFiled: February 16, 1999Date of Patent: May 22, 2001Assignee: Celltech Therapeutics, LimitedInventors: Peter David Davis, David Festus Charles Moffat, Jeremy Martin Davis, Martin Clive Hutchings
-
Patent number: 6114333Abstract: Compounds of general formula (1) ##STR1## are described wherein: Ar is an optionally substituted aromatic group;R.sup.2 is a hydrogen or halogen atom or a group --X.sup.1 --R.sup.2a where X.sup.1 is a direct bond or a linker atom or group, and R.sup.2a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group;R.sup.3 is an optionally substituted heterocycloalkyl group; and the salts, solvates, hydrates and N-oxides thereof.The compounds are selective protein tyrosine kinase inhibitors, particularly the kinases ZAP-70 and syk and are of use in the prophylaxis and treatment of immune or allergic diseases and diseases involving inappropriate platelet activation.Type: GrantFiled: October 27, 1997Date of Patent: September 5, 2000Assignee: Celltech Therapeutics Ltd.Inventors: Peter David Davis, David Festus Charles Moffat, Mark James Batchelor, Martin Clive Hutchings, David Mark Parry
-
Patent number: 6048866Abstract: Compounds of formula (1) are described: ##STR1## and the salts, solvates, hydrates and N-oxides thereof, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 have the meanings given in claim 1. The compounds are selective inhibitors of protein kinases, especially src-family protein kinases and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role.Type: GrantFiled: March 13, 1998Date of Patent: April 11, 2000Assignee: Celltech Therapeutics, LimitedInventors: Martin Clive Hutchings, Peter David Davis, David Festus Charles Moffat
-
Patent number: 5958935Abstract: 2-Anilinopyrimidines, processes for their preparation, pharmaceutical compositions containing them, their use in medicine. In a preferred embodiment, the compounds have the general formula (1): ##STR1## wherein R.sup.1 is preferably methoxy; R.sup.2 and R.sup.3 are preferably methyl; R.sup.4 is preferably a hydrogen atom; R.sup.5 is a hydrogen atom or an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R.sup.6 is a hydrogen or halogen atom or an amino (--NH.sub.2), substituted amino, nitro, carboxyl (--CO.sub.2 H), esterified carboxyl or --X.sup.1 R.sup.6a where X.sup.1 is a direct bond or a linker atom or group and R.sup.6a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; X is a direct bond or a linker atom or group; and R.sup.7 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group.Type: GrantFiled: November 19, 1996Date of Patent: September 28, 1999Assignee: Celltech Therapeutics LimitedInventors: Peter David Davis, David Festus Charles Moffat, Jeremy Martin Davis, Martin Clive Hutchings